Kornimate/medical-research-clean huggingface dataset:
the effect of inspiratory muscle training on postural control in chronic obstructive pulmonary disease

Conditions: COPD Postural Control IMT

Summary: deficits in postural control are increasingly recognized among the important secondary impairments in patients with chronic obstructive pulmonary disease (copd). there are conflicting results regarding the effect of inspiratory muscle training in improvement of inspiratory muscle strength, endurance, and dyspnea in stable copd patients. the main inspiratory muscle, the diaphragm has also a stabilizing function of the trunk. the aim of this study to enhance postural control of copd patients with improving the stability of the trunk by using inspiratory muscle training.

the study is a randomized controlled trial in patients with stable copd. the participants are divided into two groups. patients in the inspiratory muscle training (imt) group take part in a complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings completed by inspiratory muscle training. the members of the imt group use the powerbreathe medic device. the control group perform the complex pulmonary rehabilitation program without imt. the program is divided into 3 weeks inpatient period and 3 weeks home period. before, between and after the 3 weeks period all subjects are measured. 60 patients are planned to take part in the investigation. the inspiratory muscle strength is measured by powerbreathe k1 device. balance is assessed by functional balance tests: timed up and go test, four square step test, modified functional reach test, modified lateral reach test, stand up test. body sway is measured by hr mat versatek system. the diameter of the diaphragm muscle is assessed by b-mode ultrasound examination using zonare z. one ultrasound system. arterial stiffness parameters measured by arteriograph.

Eligibility criteria:
inclusion criteria: * stable copd * do not take part in other treatment * be able to learn the usage of inspiratory muscle trainer exclusion criteria: * acute exacerbation * balance problems with neurological cause * the patient unable to cooperate * participation in pulmonary rehabilitation 3 months before the study * imt use in the 3 months before the study

Keywords: copd postural control imt
uva protection factors of spf 50 and 50+ face sunscreens

Conditions: Ultraviolet-Induced Change in Normal Skin

Summary: the goal of this observational study is to use the international organization for standardization (iso) 24442:2011 in vivo method for assessment of the ultraviolet a protection factor (uvapf) of topical sunscreen products in healthy adults. the main question it aims to answer is to determine the degree of uva-protection against uva radiation. an area of each subject's skin is exposed to uva light without any protection and another (different) area is exposed after application of the sunscreen product under test. one further area is exposed after application of a reference uva sunscreen formulation (s2), which is used to validate the procedure.

the objective of the study conducted in accordance with the declaration of helsinki and national regulations regarding human studies is to evaluate the uva protection factor of the investigational products against uva, according to the iso 24442:2011 methodology comparatively to a standard product (standard s2) in healthy adult subjects. standard reference s2 sunscreen formula is used in a study if any test sample has an expected uvapf of 12 or above. the mean uvapf for the reference sample s2 is 12,7. the test result of the reference s2 uvapf must be between 10,7 and 14,7 or the test is invalid and shall be repeated. the reference s2 may be used to validate any product test. in order to determine the number of subjects, the 95 % confidence interval (ci) shall be taken into account. the 95 % confidence interval should lie within ±17 % of the mean uvapf, and a minimum of 10 subjects is required.

Eligibility criteria:
inclusion criteria: * fitzpatrick skin phototype: ii, iii or iv * colorimetric individual typology angle (ita°): 20° to 41° * intact skin on test site exclusion criteria: * pregnant or lactating women * subjects using medication with photo-sensitizing potential * subjects receiving chemotherapy or radiotherapy * subjects who have had uv exposure on the back area in the four weeks prior to uvapf testing

Keywords: sunscreen uva protection iso 24442:2011 photoprotection
the school spit study - covid-19 testing in secondary schools

Conditions: SARS-CoV2 Infection

Summary: this study will conduct an evaluation of a program that is being implemented sickkids / toronto public health that provides take-home saliva testing kits in schools. operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. the study will leverage this chance implementation to do a robust evaluation of the public health intervention. schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. the investigators will evaluate the impact of the program on sars-cov-2 case identification in schools.

this is a prospective evaluation of a program that is being implemented using a stepped-wedge, cluster randomized design. eligible secondary public schools in toronto region will be randomized. the study will occur over a 7-week period with a minimum of one-week of baseline data (control phase - testing at an assessment center, primary care or acute care center) and then schools will start the program in a stepwise manner (10 crossovers per week) with take-home saliva being available to all 60 schools by the end of the study period. the primary objective of the study is to assess whether the availability of take home saliva kits at schools for symptomatic pcr testing leads to increased diagnosis of covid-19 cases in the school.

Eligibility criteria:
secondary schools will be included in the evaluation if they are: * considered a secondary school by the school board * open for in-person learning during the study period * they have at least 100 students * offer grades 9-12 (secondary) exclusion criteria: schools that are middle schools only, that are not open for in-person learning, have fewer than 100 students or are not a complete secondary school (i.e. adult learning schools, schools offering independent courses, prep schools with 1-2 grades, secondary schools with \< 4 grades) will be excluded.

Keywords: school testing
influenza vaccination for parents and other caregivers in the pediatric medical home

Conditions: Influenza

Summary: we hypothesize that when offered influenza vaccine at little or no cost, in a setting where the value of the vaccine is connected to one's high risk child, vaccination rates for parents will approach 90-95%, similar to rates obtained in the neonatal intensive care unit environment.


Eligibility criteria:
inclusion criteria: * parents or caregiver adults who accompany at-risk children to a pediatric care outpatient clinic appointment. high risk children are defined as those 0 to 5 years of age, or who have any of the following diagnoses: * sickle cell disease * asthma * cystic fibrosis * chronic renal disease * congenital heart disease * cancer * any immunodeficiency exclusion criteria: * caregivers of children residing in group homes * persons whose children do not meet the center for disease control (cdc) definition of high-risk * persons who have had allergic reactions to influenza vaccination or any other vaccination in the past * persons who are allergic to eggs or egg products * persons who are allergic to thimerosol * previous diagnosis of guillain-barré syndrome (gbs) * persons who are moderately to severely ill at the time the vaccination is to be given

Keywords: influenza prevention
the effectiveness of 3% topical tranexamic acid compared to 4% topical hydroquinone as therapy of melasma

Conditions: Melasma

Summary: the goal of this clinical trial is to compare 3% topical tranexamic acid with 4% topical hydroquinone as therapy of melasma in patients with skin type iii-v. the main question\[s\] it aims to answer are: 1. is there a greater decrease in mmasi score after application of 3% topical tranexamic acid compared to 4% hydroquinone in melasma patients with skin type iii - v? 2. is there a greater decrease in mexameter score after application of 3% topical tranexamic acid compared to 4% hydroquinone in melasma patients with skin type iii - v? 3. are there any side effects of topical therapy of 3% tranexamic acid cream on melasma patients with skin types iii - v? participants with melasma diagnostic will apply the tranexamic acid cream and hydroquinone cream on both sides of the face differently. researchers will compare by measuring the mexameter score and mmasi score to see if there any decrease in both sides of the face.


Eligibility criteria:
inclusion criteria: * female patients diagnosed with melasma. * 18-60 years old. * fitzpatrick skin type iii to v. * willing to be a research subject (sp) and sign a consent sheet. research (informed consent). exclusion criteria: * are pregnant and/or breastfeeding * history of taking hormonal contraceptives in the last 6 months * history of topical melasma therapy: corticosteroids, tretinoin, hydroquinone, and another therapy that lightens the skin in the last 2 weeks. * use oral systemic therapy or injection in melasma, such as oral acid tranexamic, oral antioxidant, vitamin c injection, and glutathione injection in 4 last week. * history of superficial peeling therapy in the last 4 weeks. * history of deep peeling, laser or mechanical abrasion therapy in the last 6 months. * use drugs that are photosensitizers such as phenytoin, tetracycline, spironolactone, and carbamazepine. * history of bleeding disorders or being on blood-thinning therapy * allergy to tranexamic acid * difficulty in complying with treatment. * are experiencing symptoms of covid-19, such as fever, cough, sore throat, loss of sense of taste or smell, red eyes, diarrhea, rash on the skin
fluorescence guided surgery in breast cancer - the margin-2 study

Conditions: Breast Cancer; Breast Cancer Invasive

Summary: the goal of this clinical trial is to intraoperatively visualize tumour tissue in breast cancer patients using fluorescence imaging with the tracer bevacizumab-irdye800cw and thereby enhance real-time clinical decision making, preventing postoperative tumour-positive margins.


Eligibility criteria:
inclusion criteria: * patients are females with histologically proven carcinoma of the breast * the carcinoma of the breast is a local disease with limited size (but tumor size ≥ 0.5cm) and in the multidisciplinary tumor board meeting breast conserving therapy is advised. * age ≥ 18 years * written informed consent has been obtained * women of childbearing potential (premenopausal women with intact reproductive organs and women less than two years after menopause) require use of effective contraception at least 3 months before administration of the tracer (if not, a negative serum pregnancy test has to be submitted), and they need to be willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter. exclusion criteria: * medical or psychiatric conditions that compromise the patient's ability to give informed consent * non palpable breast tumor or prior surgery of this breast * received an investigational drug within 30 days prior to bevacizumab-irdye800cw * history of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure or unstable angina within 6 months prior to enrollment * inadequately controlled hypertension with or without current antihypertensive medication * significant renal or hepatic impairment (grade ii or higher deviations by ctcae) * history of allergy or infusion reactions bevacizumab or other monoclonal antibodies * pregnant or lactating women * patients receiving class ia (quinidine, procainamide) or class iii (dofetilide, amiodarone, sotalol) antiarrhythmic agents * life expectancy \< 12 weeks * preoperatively undetectable lymph nodes using spect-scan, requiring the use of patent blue
a trial of n-acetylcysteine (an over-the-counter medicine) in adolescents who smoke marijuana

Conditions: Cannabis Dependence

Summary: this study is investigating how n-acetylcysteine (nac), an over-the-counter medication, will reduce marijuana use when combined with contingency management, a behavioral treatment. it is hypothesized that marijuana dependent adolescents who are treated with nac will use less marijuana during treatment when compared to adolescents who receive a placebo.

this protocol involves investigation of n-acetylcysteine (nac) as a pharmacological treatment for cannabis dependence in adolescents. while recent advances have been made in psychosocial treatments for cannabis dependent adolescents, minimal work has been done to investigate the potential adjunctive role for pharmacotherapy in treatment. nac is an inexpensive, over-the-counter agent with a favorable tolerability profile in adults and children, in common use since fda approval in 1963. preclinical and preliminary clinical research in adults suggests a role for nac in addiction treatment via glutamate modulation.

Eligibility criteria:
inclusion criteria: * age 13-21 years * regular marijuana smoker meeting dsm-iv criteria for cannabis dependence and seeking marijuana cessation treatment exclusion criteria: * allergy or intolerance to nac * pregnancy or lactation * use of carbamazepine or nitroglycerine (or any other drug deemed to be hazardous if taken with nac) within 14 days of study participation * current enrollment in treatment for cannabis dependence * current substance dependence, other than cannabis or nicotine * significant medical or psychiatric illness that may place the participant at increased risk in the judgement of the study physician
reduced-dose chemotherapy followed by blinatumomab in induction therapy of newly diagnosed non-elderly ph-b-all

Conditions: B Acute Lymphoblastic Leukemia

Summary: blinatumomab, a cd3/cd19 bisespecific t-cell conjugative antibody, has shown high efficacy in phase i/ii studies of relapsed/refractory b-lymphoblastic leukemia (b-all), particularly in the context of low tumor burden.meanwhile, blinatumomab also plays an important role in rapid and efficient clearance of mrd in patients. therefore, its use in combination with less intensive chemotherapy for initial induction therapy in newly diagnosed patients may result in favorable response rates, greater depth of remission, and lower treatment-related toxic effects. in this study, newly diagnosed non-elderly patients with philadelphia chromosomal negative (ph-) b-all were enrolled and treated with reduced-intensity chemotherapy followed by blinatumomab as the basis of induction therapy. the clinical remission rate, mrd negative rate and treaty-related adverse reactions were evaluated in newly diagnosed non-elderly ph-b-all patients during induction therapy.


Eligibility criteria:
inclusion criteria: 1. age 15-65 2. ph-(bcr-abl1 negative)b-all was diagnosed according to who diagnostic criteria 3. newly diagnosed patients without prior induction therapy (except hydroxyurea and glucocorticoids ≦5 days) 4. ecog score 0-3 5. liver function: total bilirubin ≦ 3 times the upper limit of normal; alanine aminotransferase ≦ 3 times upper limit of normal motion; aspartate aminotransferase ≦ 3 times upper limit of normal motion; (except considering leukemia infiltration) 6. renal function: endogenous creatinine clearance ≧30ml/min 7. patients must be able to understand and willing to participate in the study and must sign the informed consent form. exclusion criteria: 1. ph+ (bcr-abl1 positive) all and known abl class ph-like all 2. t cells all 3. mature b-cell leukemia/lymphoma, b-cell lymphoma, isolated extramedullary disease 4. acute mixed-cell leukemia 5. central nervous system leukemia 6. hiv infection 7. hbv-dna or hcv-rna positive 8. patients with grade 2 or higher heart failure and other patients deemed inappropriate for inclusion by the investigator 9. pregnant or breastfeeding patients 10. the study patient was refused enrollment

Keywords: blinatumomab ph-b-all induction therapy
medicine-induced cardiac hemodialysis on covid-19

Conditions: Severe Acute Respiratory Syndrome-related Coronavirus; Renal Dialysis; Vaccines; Myocarditis Allergic; Infection Viral

Summary: the clinical trial studies the human pathogen of sars-cov-2, with a specificity in the circulating spike 2 protein in the human system. the clinical trial hypothesizes that sars-cov-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. it further hypothesizes that the vaccines do not deal with the spike 2 protein that causes the immune attacks.


Eligibility criteria:
inclusion criteria: * no mrna vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. it is theorized that the more advanced the vaccine production technology, the deeper the poisoning. exclusion criteria: * healthy individuals with no myocarditis or unvaccinated without infection by sars-cov series * persons with diabetes (paxlovid and prep treatments can be applied according to availability)

Keywords: immune infection neural infection spike 2 protein poison sars-cov-2 precarditis
long term outcome of combined phacoemulsification and excisional goniotomy with the kahook dual blade

Conditions: Glaucoma; Glaucoma, Open-Angle; Cataract; Angle Closure Glaucoma; Surgery

Summary: purpose: characterize changes in intraocular pressure (iop), iop-lowering medications, and visual acuity (va) through 3 years in patients undergoing combined phacoemulsification and excisional goniotomy with the kahook dual blade (phaco-kdb), with simultaneous goniosynechialysis in cases of angle-closure glaucoma, by a single surgeon (a.h.) in king fahd hospital of the university, dammam, saudi arabia. methods: prospective, non-comparative, uncontrolled, non-randomized interventional case series. consecutive patients with medically-treated glaucoma and visually-significant cataract underwent combined surgery. subgroup analysis of glaucoma subtypes was performed.


Eligibility criteria:
inclusion criteria: * adults 18 years or older * medically-managed glaucoma * visually significant cataract exclusion criteria: * patients undergoing any other combined procedures * active uveitis * coexisting retinopathy that limits visual acuity potential * active neovascularization * angle dysgenesis * those with less than 6 months of follow-up, were excluded.

Keywords: glaucoma goniotomy kahook dual blade combined phacoemulsification migs schlemm's canal
construction of a database for the life-cycle sepsis-specific disease cohort

Conditions: Sepsis

Summary: establish a structured clinical database for sepsis screening, and establish a special data set standard for sepsis throughout the life cycle.


Eligibility criteria:
inclusion criteria: 1. patients with sepsis who meet the sepsis 3.0 standard proposed by the 2016 international sepsis expert consensus, that is, for patients with infection or suspected infection, when sepsis-related sequential organ failure (sequential (sepsis-related) organ failure) assessment (sofa) score increased by ≥ 2 points from the baseline can be diagnosed as sepsis; 2. it is estimated that the patient's icu stay ≥24 hours; 3. obtain informed consent and sign an informed consent form. exclusion criteria: 1. the patient's icu hospital stay is less than 24 hours; 2. participated in other clinical research; 3. failed to sign the informed consent form.
folfiri as salvage treatment in metastatic biliary tract cancer (btc) patients who were failed after gemcitabine containing chemotherapy: a phase ii single arm prospective study

Conditions: Biliary Tract Cancer

Summary: folfiri as a salvage treatment in metastatic biliary tract cancer (btc) patients who failed gemcitabine containing chemotherapy

biliary tract carcinoma (btc) is rare in the europe and the united states, but not uncommon in asia and latin america. the tumor arises from the ductular epithelium of the biliary tree within the liver (intrahepatic), the extrahepatic ducts (extrahepatic), or the gallbladder. intrahepatic cancer is steadily increasing in the western world. btcs carry a poor prognosis with 1-year survival rate of 25%. although surgery remains the only curative treatment for btc, most patients present with advanced disease and die within a few months of diagnosis. while a combination of gemcitabine and platinum agents seems to be a conclusive treatment option as first-line treatment until now, the role or the optimal regimen for second-line treatment has not been established. few articles about second line treatment in advanced btc were reported. french group recently reported the retrospective analysis of folfiri regimen in advanced btc patients. however, there is no prospective trial of folfiri regimen to evaluate the efficacy and safety in advanced btc patients. so we plan this study to evaluate the efficacy and safety of folfiri regimen as a second line treatment in biliary tract cancer.

Eligibility criteria:
inclusion criteria: provision of a signed written informed consent age ≥ 20 histologically or cytologically confirmed carcinoma of biliary tract progression after treatment with first line gemcitabine-based chemotherapy ecog performance status of 0\~2 measurable lesion per recist 1.1 criteria expected life expectancy ≥ 3months adequate marrow, hepatic, renal and cardiac functions negative pregnancy test within 28 days available archival tissue or fresh biopsy exclusion criteria: poor performance statue previous treatment history of irinotecan hypersensitivity to irinotecan other primary cancer except properly treated non-melanoma skin cancer, cured cervix carcinoma in situ and other cured solid tumor without evidence of recurrence after 5 years of curative treatment. severe co-morbid illness and/or active infections any other clinical trial therapeutics within 14 days any anti-cancer therapy within 3 weeks prior to initiation of study treatment (radiotherapy, systemic chemotherapy) ctcae grade 2 or more adverse events remained intestinal obstruction or ctcae grade 3-4 upper gi bleeding within 4 weeks qtcb \> 480msec or family history of qt prolongation current heart problem such as: pooly controlled hypertension cardiomyopathy, clinically significant valvular heart disease, uncontrolled angina, acute coronary syndrome within 6 months. severe, uncontrolled systemic disease, active infection such as hbv, hcv or hiv, active bleeding tendency or history of organ transplantation